HUP9900147A2 - Terápiás szerek és autoimmun betegségek kezelésére alkalmas gyógyszerkészítmények - Google Patents

Terápiás szerek és autoimmun betegségek kezelésére alkalmas gyógyszerkészítmények

Info

Publication number
HUP9900147A2
HUP9900147A2 HU9900147A HUP9900147A HUP9900147A2 HU P9900147 A2 HUP9900147 A2 HU P9900147A2 HU 9900147 A HU9900147 A HU 9900147A HU P9900147 A HUP9900147 A HU P9900147A HU P9900147 A2 HUP9900147 A2 HU P9900147A2
Authority
HU
Hungary
Prior art keywords
treatment
pharmaceutical compositions
therapeutic agents
autoimmune diseases
autoimmune
Prior art date
Application number
HU9900147A
Other languages
English (en)
Inventor
Timothy Raymond Hirst
Toufic Osman Nashar
Neil Andrew Williams
Original Assignee
Oratol Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oratol Limited filed Critical Oratol Limited
Publication of HUP9900147A2 publication Critical patent/HUP9900147A2/hu
Publication of HUP9900147A3 publication Critical patent/HUP9900147A3/hu
Publication of HU224248B1 publication Critical patent/HU224248B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9900147A 1995-07-05 1996-07-05 Terápiás szerek és autoimmun-betegségek HU224248B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513733.7A GB9513733D0 (en) 1995-07-05 1995-07-05 Therapeutic agents
PCT/GB1996/001614 WO1997002045A1 (en) 1995-07-05 1996-07-05 Therapeutic agents and autoimmune diseases

Publications (3)

Publication Number Publication Date
HUP9900147A2 true HUP9900147A2 (hu) 1999-05-28
HUP9900147A3 HUP9900147A3 (en) 1999-11-29
HU224248B1 HU224248B1 (hu) 2005-07-28

Family

ID=10777189

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900147A HU224248B1 (hu) 1995-07-05 1996-07-05 Terápiás szerek és autoimmun-betegségek

Country Status (23)

Country Link
US (1) US6287563B1 (hu)
EP (1) EP0841939B1 (hu)
JP (1) JP4024298B2 (hu)
KR (1) KR100452000B1 (hu)
CN (1) CN1313150C (hu)
AT (1) ATE275968T1 (hu)
AU (1) AU724516B2 (hu)
CA (1) CA2225788C (hu)
CZ (1) CZ298670B6 (hu)
DE (1) DE69633393T2 (hu)
DK (1) DK0841939T3 (hu)
ES (1) ES2229276T3 (hu)
GB (1) GB9513733D0 (hu)
HK (1) HK1006496A1 (hu)
HU (1) HU224248B1 (hu)
MX (1) MX9800241A (hu)
NO (1) NO319747B1 (hu)
NZ (1) NZ311762A (hu)
PL (1) PL187266B1 (hu)
PT (1) PT841939E (hu)
RU (1) RU2203088C2 (hu)
SI (1) SI0841939T1 (hu)
WO (1) WO1997002045A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20010036917A1 (en) * 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
US7097845B2 (en) * 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
GB9800487D0 (en) 1998-01-09 1998-03-04 Oratol Limited Therapies
GB9801871D0 (en) * 1998-01-28 1998-03-25 Univ Bristol Therapies
KR20010043441A (ko) * 1998-05-08 2001-05-25 더 유니버시티 오브 브리스톨 백신용 면역조절제
AU3939499A (en) * 1998-05-08 1999-11-29 University Of Bristol, The Vaccine
EP1231931B1 (en) * 1999-11-12 2004-09-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of treating inflammatory bowel disease using cholera toxin b subunit
US7041296B1 (en) 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
US20020155511A1 (en) * 2000-09-08 2002-10-24 Carolyn Horrocks Novel antibody compositions for the negative selection of specific rat leukocyte subsets
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP2956171B1 (en) * 2013-02-14 2020-11-25 Cornell University Methods to protect against and treat multiple sclerosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent

Also Published As

Publication number Publication date
HU224248B1 (hu) 2005-07-28
CZ1298A3 (cs) 1998-06-17
KR100452000B1 (ko) 2004-11-20
US6287563B1 (en) 2001-09-11
KR19990028578A (ko) 1999-04-15
WO1997002045A1 (en) 1997-01-23
EP0841939B1 (en) 2004-09-15
NZ311762A (en) 2001-04-27
DE69633393T2 (de) 2005-11-10
PL187266B1 (pl) 2004-06-30
DE69633393D1 (de) 2004-10-21
JPH11508586A (ja) 1999-07-27
SI0841939T1 (en) 2005-04-30
AU6314296A (en) 1997-02-05
PT841939E (pt) 2005-02-28
ATE275968T1 (de) 2004-10-15
CA2225788C (en) 2010-09-21
GB9513733D0 (en) 1995-09-06
RU2203088C2 (ru) 2003-04-27
EP0841939A1 (en) 1998-05-20
DK0841939T3 (da) 2005-01-24
ES2229276T3 (es) 2005-04-16
AU724516B2 (en) 2000-09-21
CN1313150C (zh) 2007-05-02
PL324424A1 (en) 1998-05-25
JP4024298B2 (ja) 2007-12-19
CN1192693A (zh) 1998-09-09
MX9800241A (es) 1998-11-30
HK1006496A1 (en) 1999-03-05
CZ298670B6 (cs) 2007-12-19
NO980005L (no) 1998-03-05
CA2225788A1 (en) 1997-01-23
HUP9900147A3 (en) 1999-11-29
NO980005D0 (no) 1998-01-02
NO319747B1 (no) 2005-09-12

Similar Documents

Publication Publication Date Title
EP0707446A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATING NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOM COMPLEXES
AU5178296A (en) Induction of e-selectin for targetting therapeutic agents
IL161833A0 (en) Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases
HUP9903489A3 (en) Use of epinastine for the preparation of pharmaceutical compositions treating pain
ZA968907B (en) Compositions and methods for buccal delivery of pharmaceutical agents
HUP9902105A3 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
HUP9774641A2 (en) Gel for treatment of skin diseases and for disinfection of the skin
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
HUP9900147A2 (hu) Terápiás szerek és autoimmun betegségek kezelésére alkalmas gyógyszerkészítmények
HUP9904027A3 (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HUP9901303A3 (en) A pharmaceutical composition for the treatment of autoimmune diseases
PL336760A1 (en) Treatment of skin diseases
AU3937693A (en) Methods and compositions for oral delivery of therapeutic agents
EP0888381A4 (en) TARGETED THERAPEUTIC AND DIAGNOSTIC AGENTS, METHODS FOR THEIR PRODUCTION AND USE
HUP9800829A3 (en) Collagen-based methods and formulations for the treatment of immune system-mediated diseases
HUP9802197A3 (en) Peptide derivatives and pharmaceutical compositions for the treatment of t-cell mediated cartilage destruction in autoimmune diseases
AU4819993A (en) Drug for treatment and prophylaxis of bone and joint diseases
EP0687687A3 (de) Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
EP1009433A4 (en) THERAPEUTIC COMPOSITION AND TREATMENT METHOD
HUP9901935A3 (en) Dosage kit for targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)
ZA95908B (en) A synergistic formulation for treatment of rheumatic diseases
IL109235A0 (en) Pharmaceutical compositions containing ureido derivatives for the treatment of lentivirus-induced diseases
ZA968902B (en) Methods and compositions for treatment of diseases
HU9802142D0 (en) Use of na+/h+ -ion-exchange inhibitors for producing pharmaceutical compositions for treating and profilacting diseases of the central nerve system

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050517

GB9A Succession in title

Owner name: TRIDENT PHARMACEUTICALS, INC., US

Free format text: FORMER OWNER(S): ORATOL LIMITED, GB; UNIVERSITY OF BRISTOL, GB

MM4A Lapse of definitive patent protection due to non-payment of fees